Since IL-33 overexpression and treatment potentiates BLM-induced fibrosis [14, 16], IL-33 has been proposed to act as a key pro-fibrotic mediator during the development of IPF. This evidence concerns the gene IL33 and idiopathic pulmonary fibrosis.